Two juvenile size silicone testicular prostheses were analyzed following replacement by adult size devices after 72 and 99 months in situ. Scanning electron microscopy and electron microprobe studies were carried out on the explanted silicone prostheses and their attached tissue capsules. The material at the surface of the prostheses gave no evidence of biodeterioration. However,…
Journal d'urologie Template
Write in a clean editor, then format for Journal d'urologie in one click — DocuGuru applies the official Elsevier template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
About the Journal d'urologie format
Journal d'urologie is a peer-reviewed journal published by Elsevier, covering Renal cell carcinoma treatment, Renal and Vascular Pathologies, Urologic and reproductive health conditions.
| Publisher | Elsevier |
|---|---|
| Reference style | Numbered (Elsevier) Numbered — [1], [2] in the text [1] A. Smith, B. Jones, C. Lee, A representative article title, Journal d'urologie 12 (2023) 45–58.
Formats any DOI in Journal d'urologie style. No sign-up. |
| Publishes research in | Renal cell carcinoma treatment Renal and Vascular Pathologies Urologic and reproductive health conditions Bladder and Urothelial Cancer Treatments Adrenal and Paraganglionic Tumors |
| ISSN | 0248-0018 |
| h-index | 4 |
| i10-index | 2 |
| Total citations | 94 |
| Top institutions publishing here | Kaiser Permanente |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Papers published in Journal d'urologie per year
Citation impact of Journal d'urologie by publication year
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Most-cited papers in Journal d'urologie
From January 1981 until December 1983, 51 patients have been submitted to total cystectomy for infiltrative bladder cancer, stages B2 C and D1 of the Marshall classification. They have be proposed in a trial of feasibility with adjuvant chemotherapy using Adriamycin and Cis Platinum. 24 patients have been excluded, 17 because medical contraindications, 5 because…
From a series of 39 patients presenting with a locally advanced cancer of the prostate (Stage C), 26 were treated with an LH-RH analogue, Buserelin, for a period ranging between 7 and 22 months. After an initial period of subcutaneous injections, the treatment was administered by intranasal spray (400 mcg three times a day). This…